PLS-α-GalCer: a novel targeted glycolipid therapy for solid tumors

Background The prototypical type I natural killer T (NKT) cell agonist, α-galactosylceramide (α-GalCer), has shown only minimal effects against solid tumors in the clinic. The most promising clinical application of α-GalCer currently entails ex vivo priming of patient-derived dendritic cells; howeve...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jay A Berzofsky, Shweta Tiwary, Julian Burks, David M Stevens, Sarah L Skoczen, Ruvanthi N Kularatne, Stephan T Stern
Format:	Artigo
Idioma:	Inglês
Publicat:	BMJ Publishing Group 2025-03-01
Col·lecció:	Journal for ImmunoTherapy of Cancer
Accés en línia:	https://jitc.bmj.com/content/13/3/e009539.full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!